NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Cat Livingston, MD; Stacy Ramirez, PharmD; Tim Langford, PharmD; Caryn Mickelson, PharmD; Robin Moody, MPH; Bill Origer, MD; Russ Huffman, PMHNP; Patrick DeMartino, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Amanda Parish, LCSW; Sarah Servid, PharmD; Megan Herink, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD; Deborah Weston, JD

Audience: Ashlee Waring, AstraZeneca; Becky Gonzales; Ben Dillon; Brandie Feger, Advanced Health; Camille Kerr; Carol Vuceta, Sanofi; China Izatt, Takeda Oncology; Jill Conner, Sanofi; Craig Sexton; Deb Profant; Jack Meloro, EveryLife Foundation for Rare Diseases; Jason Kniffin; John Breen, SOBI Account Director; John McDonald, Scynexis Dir Nat Accts; Jordana Wollman, AstraZeneca*; Kendra Davies; Laura Jeffcoat, AbbVie; Heidi Kresken, Scynexis*; Lee Stout, Chiesi USA; Madeline Shurtleff; Matt Worthy, OHSU; Melissa Roy, Otsuka; Melissa Walker, Arinia Pharmaceuticals; Michael Foster, BMS; Michele Sabados, Alkermes; Michelle Plotner, AstraZeneca; Mike Donabedian, Sarepta Therapeutics; Nana Ama Kuffour, IHN; Nicole Slawny, Aurinia Pharmaceuticals*; Olaf Reinwald, GBT; Paul Thompson, Alkermes; Raffaella Colzani, Sanofi Genzyme*; Roy Lindfield, Sunovion; Saghi Maleki; Takeda Pharmaceuticals; Dennis Schaffner, Sanofi; Sean Staff; ChemoCentryx; Sophia Yun, Janssen; Steve Angelcyk, BD Diabetes; Tiina Andrews, UHA; Stefanie Uhrich; YJ Shukla, MODA Health

(*) Provided verbal testimony
Written testimony: Posted to OSU Website
I. CALL TO ORDER

A. Roll Call & Introductions
   - Called to order at approx. 1:02 p.m., introductions by Committee and staff
B. Conflict of Interest Declaration – no new conflicts of interest were declared
C. Election of Chair and Vice-Chair
   Dr. Ramirez volunteered to again serve as Chair and Dr. Origer as Vice-Chair
   ACTION: Motion to approve, 2nd, all in favor
D. Approval of Agenda and December 2021 Minutes presented by Roger Citron
   ACTION: Motion to approve, 2nd, Dr. Saito abstained and everyone else in favor
E. Department Update provided by Andrew Gibler, PharmD
F. Legislative Update provided by Dee Weston, JD

II. CONSENT AGENDA TOPICS

A. P&T Annual Report
B. P&T Operating Procedures
C. P&T Methods
D. Parenteral Antipsychotics Literature Scan
   Recommendations:
   - No PDL changes recommended based on the clinical evidence
   - Evaluate costs in executive session
E. Inhibitors of the Renin-Angiotensin-Aldosterone System (RAAS) Literature Scan
   Recommendations:
   - No PDL changes recommended based on the clinical evidence
   - Evaluate costs in executive session
F. Oncology Prior Authorization (PA) Updates
   Recommendations:
   - Add: Besremi® (ropoginterferon alfa-2b-njft); and Fyarro™ (sirolimus albumin-bound nanoparticles) to Table 1 in the Oncology Agents prior authorization (PA) criteria
   ACTION: Motion to approve, 2nd, all in favor

III. DUR ACTIVITIES

A. Quarterly Utilization Report: Roger Citron, RPh
B. ProDUR Report: Lan Starkweather, PharmD
C. RetroDUR Report: Dave Engen, PharmD
D. Oregon State Drug Review: Kathy Sentena, PharmD
   - Therapeutic Uses for Cannabinoids
   - Updates in Heart failure Therapy: New Drugs and Indications
IV. DUR NEW BUSINESS

A. Respiratory Syncytial Virus (RSV) Literature Scan and Policy Update:
Kathy Sentena, PharmD
Recommendation:
- Update the RSV PA criteria to correlate with state guidance on season onset
ACTION: Motion to approve, 2nd, all in favor

V. PREFERRED DRUG LIST NEW BUSINESS

A. Oral Antifungals Class Update with New Drug Evaluation (NDE):
Kathy Sentena, PharmD
Recommendations:
- No PDL changes recommended based on the clinical evidence
- Maintain Brexafemme® (ibrexafungerp) as non-preferred on the PDL
- Evaluate costs in executive session
Public Comment: Heidi Kresken, Scynexis
ACTION: Motion to approve, 2nd, all in favor

B. Pompe Disease Class Update with NDE: Dave Engen, PharmD
Recommendations:
- Add Nexviazyme™ (avalglucosidase alfa) to the Lysosomal Storage Disorders class and designate as non-preferred
- Update the PA criteria for Pompe Disease drugs to include avalglucosidase alfa
- Evaluate costs in executive session
Public Comment: Raffaella Colzani, Sanofi Genzyme
ACTION: The Committee recommended amending the proposed criteria so that question #5 asks for provider assessment of risk factors for adverse events and so that question #14 asks whether baseline tests have been performed
Motion to approve, 2nd, all in favor

C. Immunosuppressant Class Update with NDEs: Sara Fletcher, PharmD
Recommendations:
- No PDL changes recommended based on the clinical evidence
- Move Saphnelo™ (anifrolumab-fnia) into the TIMS class
- Update belimumab PA criteria
- Implement PA for voclosporin to ensure appropriate use
- Implement PA for anifrolumab-fnia with proposed edits
- Evaluate costs in executive session
Public Comment: Jordana Wollman, AstraZeneca; Nicole Slawny, Aurinia Pharmaceuticals
ACTION: Motion to approve, 2nd, all in favor

E. Oral Glucocorticoids Class Review: Deanna Moretz, PharmD
Recommendations:
- Add the Oral Glucocorticoids class to the PDL
- Add at least one oral formulation of each glucocorticoid to the PDL after review of costs in the executive session
ACTION: Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Cat Livingston, MD; Stacy Ramirez, PharmD; Tim Langford, PharmD; Caryn Mickelson, PharmD; Bill Origer, MD; Russ Huffman, PMHNP; Patrick DeMartino, MD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Megan Herink, PharmD; Brandon Wells; Kyle Hamilton; Andrew Gibler, PharmD; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD; Deborah Weston, JD

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Parenteral Antipsychotics Literature Scan
Recommendation: Make Invega Hafyera preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

B. Inhibitors of the RAAS Literature Scan
Recommendation: Make fosinopril, quinapril, candesartan preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

C. Oral Antifungals Class Update and NDE:
Recommendation: No changes to the PDL are recommended
ACTION: Motion to approve, 2nd, all in favor

D. Pompe Disease Class Update and NDE
Recommendation: No changes to the PDL are recommended
ACTION: Motion to approve, 2nd, all in favor
E. **Oral Glucocorticoids Class Review**

**Recommendation:** Make the following agents non-preferred on the PDL: Hemady®; Alkindi® Sprinkle; Pediapred®; Millipred™; prednisolone sodium phosphate solution; and prednisolone sodium phosphate disintegrating tablets. The Committee recommended making all other currently available oral formulations preferred on the PDL. New oral glucocorticoid formulations will be designated non-preferred until reviewed by the Committee.

**ACTION:** Motion to approve, 2nd, all in favor

---

**VII. ADJOURN**